Lakefront Previews ASH Data: Gamgertamig Shows 90% ITP and 100% AIHA Response Rates
LKFT sits 30% above its 52-week low of $25.68 on light trading volume (0.1× avg).
Summary
Lakefront disclosed first company-sponsored Phase 1b data for gamgertamig showing 90% response in ITP and 100% in AIHA with only Grade 1 CRS, ahead of an ASH poster on December 13 and an investor call on December 14.
Key Events · Product Development and Regulatory · LKFT
-
ASH Poster Accepted for Gamgertamig
Poster 3008, scheduled for December 13, 2026, presents initial global clinical experience with gamgertamig in relapsed/refractory autoimmune cytopenias from two parallel studies (NCT07083960, NCT07175493).
-
High Response Rates in Phase 1b
In ITP, 18/20 (90%) responded, including 12/12 (100%) in the high dose cohort, with platelet normalization in 17/18 responders. In AIHA, 9/9 (100%) response-evaluable patients responded.
-
Responses Durable at Follow-Up
At median follow-up of 141 days and 85 days, respectively, 15 of 18 ITP responders (83%) and 8 of 9 AIHA responders (89%) had ongoing responses.
-
Clean Safety Profile
Grade 1 CRS occurred in 6/33 patients (18%), with no Grade >=2 CRS and no ICANS or other neurotoxicity; infections occurred in 10/33 (30%), mostly Grade 1-2 and all managed.
Analysis · LKFT · Life Sciences
The first company-sponsored Phase 1b numbers for gamgertamig — the asset Lakefront was built around after the Ouro/Gilead deal — are strong. In ITP, 18 of 20 evaluable patients responded; in AIHA, every evaluable patient responded, and most responses remained ongoing at a median 141 days (ITP) and 85 days (AIHA). Safety looks manageable, with only Grade 1 cytokine release syndrome and no neurotoxicity — a key point, since CRS and ICANS are the usual failure modes for T-cell engagers. Management says gamgertamig enters registrational studies in 2027, making the December 13 ASH poster and December 14 investor call the next checkpoints where the full dataset gets scrutinized.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2221 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LKFT was trading at $33.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.68 to $36.24. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.